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Abstract
Purpose: Preclinical models of epithelial ovarian cancer have not been exploited to evaluate the clinical standard
combination therapy of surgical debulking with follow-up chemotherapy. As surgery is critical to patient survival, here we
establish a combined surgical/chemotherapy xenograft model of epithelial ovarian cancer and demonstrate its translational
relevance.
Experimental Design: SKOV-3luc+ ovary cancer cells were injected topically into the ovaries of immunodeficient mice.
Disease development and effect of clinical standard treatment including hysterectomy, bilateral salpingoophorectomy and
removal of metastasis with follow up chemotherapy (carboplatin 12 mg/kg + paclitaxel 15 mg/kg) was evaluated by clinical
parameters. Tumor burden was quantified by bioluminescence imaging (BLI).
Results: The xenograft ovarian tumors developed were poorly differentiated and multicystic and the disease disseminated
into the peritoneal cavity. When compared to the controls with a mean survival time of 4.9 weeks, mice treated with surgery
and chemotherapy, surgery or chemotherapy demonstrated significantly improved mean survival of 16.1 weeks (p = 0.0008),
12.7 weeks (p = 0.0008), or 10.4 weeks (p = 0.008), respectively.
Conclusion: Combined surgical intervention and adjuvant chemotherapy was demonstrated for the first time in an
orthotopic xenograft model of ovarian cancer. Similar to observation in human studies the combined approach resulted in
the longest medial survival time, advocating application of this strategy in future preclinical therapeutic development for
this disease.
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Introduction
Epithelial ovarian cancer (EOC) represents about 5% of all
cancers in females worldwide and is the leading cause of neoplasm-
related deaths among gynecological diseases in the Western world
[1]. Debulking surgery is the cornerstone in EOC treatment with
the aim of maximum cytoreduction [2,3]. First-line adjuvant
chemotherapy, a combination of platinum-paclitaxel, yields
response rates above 80%, including 40–60% complete responses,
and improve both overall and progression free survival in all
patient subgroups [4,5]. However, most patients will later relapse
and succumb to their disease due to innate or acquired drug
resistance [6]. Despite improvement of surgical techniques and
chemotherapeutic regimens, the overall 5-year survival rate is still
below 45% [1]. New strategies, including improvement of today’s
standards of care, substantiated in relevant preclinical models are
critical should survival rates be improved.
Preclinical evaluation of therapy in ovarian cancer has been
predominantly performed in murine experimental models [7–9].
The syngeneic, genetically engineered mouse models (GEMM)
and xenograft systems described mimic different aspects of the
complexity of EOC [10]. Whereas an intact immune system in
syngeneic models allows evaluation of host-tumor interactions
[11], GEMM have their greatest application in unravelling the
molecular basis of disease. However, a caveat in the application of
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e89527
GEMM relates to the relative indiscriminate nature of the genetic
insertion process, which may often result in unrepresentative
models of EOC. Moreover, syngeneic models are not human
disease. Subsequently, results gleaned from preclinical drug
screening in such systems may have questionable clinical relevance
[10]. As such, xenograft EOC models of defined human cell lines
are possibly a more ideal approach to study the chemo-sensitivity
of both cytotoxic therapeutics and targeted agents [10,12].
Generally, xenograft models of EOC have exploited the subcu-
taneous and intraperitoneal routes, owing primarily to the
simplicity and ease of both inoculations of cells and to monitor
therapeutic intervention. Inoculation of human cells or cell lines
into orthotopic sites may nevertheless be clinically more relevant
as they also replicate the early stages of tumor development
[8,10,13,14].
Bioluminescence imaging (BLI) has an important role in both
therapeutic and molecular imaging of orthotopic xenografts of
EOC [15–17]. However, despite advances in orthotopic xenograft
model development and progression of preclinical imaging
techniques of immunodeficient hosts [18], surgical intervention,
i.e. the backbone of clinical therapeutic regimes in ovarian cancer
[2,19], has not been applied in a preclinical setting. Preclinical
orthotopic xenografts have thus far exclusively been used to
analyze the effect of cytostatics and new therapeutics [5,20].
Therefore, the objective of this study was to evaluate surgical
intervention together with a standard adjuvant chemotherapy
regimen in a preclinical orthotopic xenograft model.
To achieve this we established a bioluminescent orthotopic
EOC model of ovarian cancer based on the SKOV-3 cell line
expressing luciferase. Xenografts disseminated into the peritoneal
cavity and resulted in ascitic fluid formation analogous to what
detected de novo in EOC patients. Primary tumor tissues detected
by BLI were surgical removed and the effect of surgical
intervention alone and/or in combination with intraperitoneal
carboplatin-paclitaxel adjuvant chemotherapy in an EOC mouse
model was demonstrate for the very first time.
Materials and Methods
Cell lines and reagents
The human ovarian adenocarcinoma cell line SKOV-3 (ATCC
HTB-77) was obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were cultivated in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Paisley,
UK) supplemented with 10% heat-inactivated fetal calf serum
(FCS; Gibco), 2 mM L-glutamine (Gibco) and penicillin 100 IU/
ml and 100 mg/ml streptomycin (Gibco) at 37uC in a humidified
atmosphere with 5% CO2. Cells were grown in 75 cm
2 cell culture
flasks (Costar, Cambridge, MA, USA) and subcultured twice a
week. Suspensions of the cells were obtained by washing the cells
twice with 10% phosphate buffered saline (PBS; Dulbecco’s
tablets, Oxoid Limited, Hampshire, UK) and incubating the cell
cultures with Trypsin EDTA (Gibco). Thereafter, the cells were
washed in growth medium, resuspended or snap-frozen for later
thawing and reuse [21].
Retroviral transfection of SKOV-3 cells
SKOV-3 clones stably expressing luciferase, denoted SKOV-
3luc+ were engineered using the luciferase expressing construct,
L192, coding for the luciferase enzyme and co-transduced with the
tetracycline-regulated transactivator (tTA) which has a promoter
localized upstream of L192 that drive the expression of the
luciferase enzyme. Retroviral infection was performed as described
earlier [22]. L192 has a puromycine resistance gene, and after two
passages the cells were selected with puromycine 2 mg/ml. (Sigma-
Aldrich, Oslo, Norway, stock: 25 mg/ml diluted in 0.9% sterile
NaCl). Before injecting the transfected cells into animals, luciferase
expression was tested. 10 ml D-luciferin (Promega, Madison, WI,
USA, 150 mg/ml) was added 10 minutes prior to optical imagine to
100 ml cell suspensions containing 16105 cells in a 96-well plate
(Costar).
DNA fingerprinting
For DNA fingerprinting, genomic DNA was isolated from
primary SKOV-3 cells, the SKOV-3luc+ cells and xenografted
SKOV-3luc+ by the Tissue DNA kit (EZNA OMEGA Bio-tek,
Norcross, GA USA, Cat.no. D3396-02) according to the manu-
facturer’s protocol for purification of total DNA from cells. DNA
concentration was determined by a Powerwave spectrophotometer
by OD readings at 260 nm. The AmpFlSTR Profiler Plus PCR
Amplification Kit (Applied Biosystems, Foster City, CA, USA) was
employed according to the manufacturer’s protocol using 1.25 ng
DNA, 25 ml reaction volume and 28 amplification cycles. This kit
amplifies nine tetranucleotide short tandem repeat loci and the
amelogenin locus in a single reaction. Samples were run and allele
sizes interpreted on an ABI 3100 Genetic Analyzer with Gene
Mapper v3.7 software (both from Applied Biosystems) [23].
Histology and immunhistochemistry
For histopathological examination, tissue sections (4 mm) were
stained with hematoxylin and eosin (H&E) before they were
examined by an experienced pathologist (OKM). The immuno-
histochemistry (IHC) staining was performed on formalin-fixed
and paraffin-embedded ovarian tumor tissue sectioned at 4 mm
thickness. After de-paraffination in xylene and rehydration
through graded ethanol series and distilled water solution, the
tissues were subjected to heat-induced epitope retrieval undertaken
in TRS (Target Retrieval Solution), pH 9.9 (DakoCytomation,
Copenhagen, Denmark, S3307) or citrate buffer (pH=6.0) by the
use of microwave oven at 350 W for 15 minutes. Proteinase K
(Dako) endogen peroxidase activity was blocked with 0.3%
peroxidase (Dako) for 5 minutes. The sections were incubated
with the following primary antibodies in room temperature for
30 minutes: Monoclonal Mouse Anti-Human Cytokeratin, clone
MNF116, Monoclonal Mouse Anti-Human Vimentin, clone V9,
Monoclonal Mouse Anti-Human Epithelial Antigen, clone Ber-
EP4, Anti-Human Wilms Tumor 1 (WT1) Protein, clone 6F-H2
(Dako, Glostrup, Denmark) and Monoclonal Mouse Anti-TAG-
72, clone B72.3 (BioGenex, Fremont, USA). The staining was
performed using a DAKO autostainer using the EnVision (DAKO
5007) as secondary antibody for 30 minutes for all primary
antibodies. Diaminobenzine, DAB was used as chromogen for
10 minutes in development of all antibodies. Sections were
counterstained with hematoxylin (Dako S3301 for 3 minutes,
dehydrated and mounted in Eukitt (O. Kindler GmbH & Co,
Freiburg, Germany). Negative control sections underwent the
same procedure but without including primary antibody. Human
tissue from high-grade serous ovarian carcinoma with known
reactivity to the selected markers was used as positive control.
Animals
The protocol for animal studies was approved by the Norwegian
State Commission for Laboratory Animals (ID 3417) and the
experiments were performed according to the European Conven-
tion for the Protection of Vertebrates Used for Scientific Purposes.
Female NSG mice (6–8 weeks old; Vivarium, University of
Bergen) were maintained under defined flora conditions in
individually ventilated (HEPA-filtered air) sterile microisolator
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Figure 1. Characterization of the experimental in vivo mouse model. (A), DNA fingerprinting illustrating unique shared microsatellite DNAs
between native SKOV-3, mutant SKOV-3luc+, and in vivo xenografted SKOV-3luc+ cells. (B), Illustration of in vivo bioluminescence imaging of orthotopic
SKOV-3luc+ cells from one representative untreated control mouse. (C), Relative mean tumor growth vs time as determined by bioluminescence
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cages (Techniplast, Buguggiate, Italy) at the University of Bergen’s
animal facility. No more than five mice were in each individually
ventilated cage that was kept on a 12 hr dark/night schedule at a
constant temperature of 21uC and at 50% relative humidity.
Bedding and cages were autoclaved and changed twice per month.
The mice had continuous supply of sterile water and food and
were monitored daily by the same personnel for the duration of the
experiment and weighed three times per week. Under depilation
(shaving and depilatory cream) and imaging, mice were anesthe-
tized with 3% isoflurane (Isoba Vet, Schering-Plough, Brussel,
Belgium).
Orthotopic ovarian cancer model
Mice were anesthetized with isoflurane 3% and placed on a
heating pad in lateral decubitus. The fur was clipped on the left
lateral side of the abdomen, from the thoraco-lumbar junction to
the iliac crest. Skin was disinfected with chlorhexidine 5 mg/ml,
(Fresenius Kabi, Halden, Norway) and 70% ethanol (Kemetyl,
Vestby, Norway). A 5 mm incision was made in the skin and
abdominal wall, parallel and ventral to the spine, midway and
between the last rib and the iliac crest. The ovarian fat pads were
exteriorized and the ovaries were held in position facing the
surgeon with the oviduct ventral, using a serrefine clamp. The cell
suspensions (10 mL) containing 16104 SKOV-3luc+ cells, were
inoculated inserting the needle (30 gauge) at the junction between
the bursa and the fat pad. Before closing muscles and skin with
continuous 5-0 monofilament non-absorbable sutures (Ethilon 5-0,
Johnson & Johnson, New Brunswick, NJ, USA) the ovaries were
put back to the original position. After the surgery the animals
received 0.1 mg/kg buprenorphine hydrochloride (Temgesic,
Reckitt Benckiser, Berkshire, UK) and were placed in a warm
environment until full recovery.
Surgery (hysterectomy, salpingoophorectomy and
debulkment)
Mice were anesthetized in the same manner as for orthotopic
injection and were placed in dorsal recumbence with the tail
towards the surgeon. The abdominal area was shaved and
swabbed with chlorhexidine and ethanol. A 2 cm midline incision
was made through the skin, subcutaneous fat, muscles and linea
alba. After opening the peritoneum with a scissor the abdomen
was explored. Ascites, if present, was removed and staging of the
cancer disease in each mouse was performed according to the
FIGO system [24]. The ovaries and uterus were then removed.
The ovary vein and artery were identified in mesometrium and
cauterized close to the ovary on each side using a low temperature
cautery, fine tip (Aaron Medical, St Petersburg, Russia). There-
after, a single ligature with 5-0 silk suture Deknatel; (Silk-Fine
Science Tools, Teleflex, NY, USA) was placed around cervix and
cervix was cut with a scissor above the ligature before the uterine
horns and ovaries were taken out. Any visible metastases in the
peritoneum (omentum and mesentery) or adipose tissue were also
eradicated. Skin and muscles were closed separately using non-
absorbable suture material. The animals were kept under
observation until they completely recovered from the anesthesia,
and analgesics were administrated if needed [25].
Chemotherapy
In this study, we chose an intraperitoneal route for administra-
tion of chemotherapy because it is less demanding to administrate
in mice. Moreover, in human studies intraperitoneal delivery has
at least the same response rate as the intravenous route and
therefore are used more and more in clinical practice [26]. To
determine the maximum tolerable dosage (MTD) of carboplatin
(Teva, Helsingborg, Sweden 10 mg/ml) and paclitaxel (Fresenius
Kabi, Halden, Norway 6 mg/ml), the following different dosages
were evaluated. Carboplatin 15, 20 or 30 mg/kg, paclitaxel 12, 16
or 20 mg/kg as monotherapy or combined (n=3 mice per group,
total 27 mice) twice weekly for three consecutive weeks (Q2Wx3).
Body weight was monitored for 28 days. A combination consisting
of carboplatin 15 mg/kg together with paclitaxel 12 mg/kg was
found to be the MTD. At the end of study the mice were
euthanized.
Design of trial
The mice were randomized into 4 different treatment arms with
6 mice in each group (n=6): (a) control, (b) surgery alone
(hysterectomy, bilateral salpingoophorectomy and removement of
metastasis if present), (c) carboplatin 15 mg/kg + paclitaxel
12 mg/kg, Q2Wx3 and (d) surgery followed by carboplatin
15 mg/kg + paclitaxel 12 mg/kg Q2Wx3. Efficacy was evaluated
throughout the study by BLI.
Optical imaging (In vivo and ex vivo)
10 minutes before optical imaging with an Optix MX2 Small
Animal Molecular Imager (ART Inc., Saint-Laurent, QC,
Canada). Optix Optiview (version 2.00.01, ART Inc.) the mice
were injected i.p. with D-luciferin (150 mg/kg). Whole body
image analysis. (D), Kaplan-Meier survival curve for untreated xenografted mice (n = 10). E, Illustrations of tumor manifestations in various organs in
surgical specimens (photographs), by bioluminescence imaging (BLI), and morphology (H+E). Tumors are denominated ‘‘T.’’ Tumor delineation
against normal tissue is indicated by dashed line on H-E staining.
doi:10.1371/journal.pone.0089527.g001
Table 1. Tumor engraftment and tumor progression.
(%)
Graft take 100
Metastatic incidence 100
Pelvic metastasis
Bladder 80
Ovary 70
Lymph nodes metastasis
Para-aortic lumbar 70
Para aortic renal 50
Mesenteric 40
Abdominal metastasis
Peritoneum 100
Pancreas 80
Liver 60
Kidney 80
Spleen 70
Distal metastasis
Thoracic 50
Xenograft disease characteristics. Data is derived from 10 xenografted mice.
doi:10.1371/journal.pone.0089527.t001
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imaging in addition to imaging and examination of single organs
removed after euthanasia was performed.
Necropsy
The health status and the weight of the mice were monitored
daily and mice were humanely euthanized when moribund as
defined by; weight loss .10–15%, lethargy or ruffled fur. The
post-mortem examination included macroscopic description of the
primary tumor, metastasis and ascitic fluid. All organs were
imaged ex vivo to give a further description of metastasis. The
tissue biopsies were fixed in 4% buffered formalin and embedded
in paraffin before they were processed for histological analysis or
snap-frozen in liquid nitrogen.
Statistical methods
Survival data was analyzed using the Kaplan and Meier
method. The Mantel-Haenzel log-rank statistics (GraphPad Prism
5.0, GraphPad Software, La Jolla, CA) was used to analyze
survival distribution. Survival times are quoted as mean 6
standard error of the mean (SEM). Prior to initiation of the
therapeutic study, xenografted mice were randomized into groups
based on BLI and body weight (i.e. no individual mouse
demonstrated .20% differences in either body weight or BLI
from group counterparts) and ANOVA performed to ensure that
there were no statistical differences between groups. For all
statistical analysis, p,0.05 was regarded significant.
Results
Generation of stable, high luciferase expressing SKOV-3
cells and DNA microsatellite analysis
To develop a bioluminescent ovarian cancer cell line to permit
longitudinal spatio-temporal monitoring of orthotopic xenografts,
the ovarian adenocarcinoma cell line SKOV-3 was transfected
with a luciferase reporter as previously described [27]. Stably
transfected SKOV-3luc+ were selected with puromycin. The DNA
microsatellite analysis of SKOV-3luc+ and wild-type SKOV-3 cells
showed identical fingerprint patterns (Fig. 1A). Moreover, a
comparison of DNA fingerprints with the data published for the
SKOV-3 cell line in the ATCC database (www.atcc.org)
established that the cells have the same origin.
Orthotopic xenograft model
To generate a bioluminescent xenograft model of SKOV-3luc+
cells, the mice underwent a laparotomy by a 5 mm incision, the
ovary was exteriorized and approximately 16104 SKOV-3luc+
cells were injected orthotopically into the left ovary of NSG mice.
BLI was performed weekly (Fig. 1B). Initially, the bioluminescence
was detected only at the injected ovary (week 1) and in the
following two weeks disease progression, with infiltration and
metastasis to the right ovary, was observed with a log increase in
BLI signal (Fig. 1C). Full metastatic dissemination of the entire
abdomen and thoracic cavity was observed from week 3 (Fig. 1B).
Clinically, at the final week of follow-up, all mice had generated
progressive volumes of ascites, defined by weight gain and pallor.
The ascites were hemorrhagic and recovered volumes from
peritoneal aspirates varied between 0.5 to 4 ml (data not shown).
In general, mice orthotopically implanted with SKOV-3luc+ cells
(n=10) exhibited a consistent disease pattern with mice succumb-
ing to terminal disease within 4.960.2 weeks (Fig. 1D). Previously,
primary patient ovarian cancer samples have been demonstrated
to exhibit genetic instability following xenograft in NSG mice,
affecting reproducibility of that xenograft system [28]. DNA
fingerprinting analysis of xenografted SKOV-3luc+ cells from our
Figure 2. Morphological evaluation of human vs xenografted
mice ovarian serous adenocarcinomas. The left column shows a
high-grade serous adenocarcinoma from human ovary. The right
column shows a mouse with a representative ovarian xenograft derived
from human SKOV-3luc+ cells. (A), Formalin fixed paraffin embedded
H+E stained sections of human (left) vs xenografted (right) mice (106
magnification), (B–F), Detection of various cancer protein biomarkers
(Ber-EP4, cytokeratin, TAG72, vimentin, and WT1) by immunohisto-
chemistry in human (left) vs xenografted (right) mice (106magnifica-
tion).
doi:10.1371/journal.pone.0089527.g002
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orthotopic model was consistent with the parental and luciferase
transfected cell lines (Fig. 1A). At necropsy, a macro-anatomical
description and ex vivo BLI analysis revealed not only primary
ovarian tumors as anticipated but also extensive local and distal
metastasis as described in Table 1 and illustrated by ex vivo
bioluminescence imaging, photography and histology (Fig. 1E).
Characterization of orthotopic tumors by histopathology
and immunohistochemistry analysis
Histological analysis of the tumor grafts including the metastases
showed that the mice had developed a highly invasive growing
tumor with markedly pleomorphic nuclei with increased nuclear to
cytoplasmic ratios.
Immunohistochemistry analysis of both the xenografts as well as
the human tumor tissue demonstrated an epithelial phenotype
with positive staining for BerEp4, cytokeratin PAN and TAG-72
(Fig. 2). Only the stroma of the human tumor and not the one in
the xenografts showed positive staining for Vimentin and WT-1
(Fig. 2).
Preclinical Surgery and combination chemotherapy in a
bioluminescent orthotopic xenograft model of ovarian
cancer
The main criterion in development of this novel xenograft
model of ovarian carcinoma was to enable therapeutic regimes
that incorporated surgical intervention and permitted comparison
of chemotherapy and surgery in the same model. Thus, 24 NSG
mice were orthotopically implanted in the left ovary with 16104
SKOV-3luc+ cells and disease progression monitored by BLI.
Following establishment of primary ovarian tumors and prior to
identification of metastasis by BLI, mice were randomized into
four groups each with six mice per group; (A) control, (B)
combination chemotherapy with carboplatin (15 mg/kg) + pacli-
taxel (12 mg/kg) administered twice weekly and repeated for three
weeks, (C) surgery (i.e. hysterectomy, salpingoophorectomy and
evident metastasis; illustrated in Fig. 3) and (D) combined surgery
and chemotherapy with therapeutic intervention monitored by
BLI (Fig. 3 and 4A).
When operated, all mice had developed a tumor localized in the
ovary. Most tumors were confined to the injected ovary, but three
mice had already developed macroscopic visible tumors in the
peritoneal lining in pelvis. According to the staging system of the
International Federation of Gynecology and Obstetrics (FIGO) the
mice had all stage IA to IIB.
As anticipated, all control mice developed progressive tumor
growth and log increase in bioluminescence as previously observed
(Fig. 4A). They were moribund within 4.960.5 weeks (Fig. 4 A–
D). In comparison, mice treated with combination chemotherapy
at week 0 and maintained on chemotherapy for three weeks,
demonstrated stabilized disease for up to two weeks post-
chemotherapy, before relapse to moribund condition within
10.461.2 weeks. In contrast, the surgical cohort initially demon-
strated absence of bioluminescence in all mice following surgery
on week 0. However the recurrence rate was 100% and all mice
relapsed to moribund condition in 12.762.7 weeks. No significant
differences between surgical and chemotherapeutic cohort
(p=0.70) was observed. Finally, the cohort treated with debulking
surgery followed by adjuvant cytostatics replicated clinical
response with the greatest debulkment of disease and therapeutic
response. Indeed, overall survival was extended to 16.162.9 weeks
with one mouse considered cured with no bioluminescence
observed even after 40 weeks of follow-up (Fig. 4 A). While all
the three treatment regimens showed significant improvement of
survival rate (p,0.05) when compared to controls (Fig. 4 C and D),
significantly curative treatment was only observed following
combination of surgical intervention and cytostatics, replicating
the clinical picture in EOC patients.
Figure 3. Surgical procedures and monitoring of tumor growth in xenografted mice by bioluminescence image analysis. (A),
Preoperative bioluminescence imaging of a representative xenografted (SKOV-3luc+ cells) mouse (dorsal aspect) with colour bar illustrating photon
counts per raster scan point (1 mm2). (B–D), Illustrations of various routine surgical procedures with exposure of right tube (B), ovary (C) and after
closure of the incision in the mouse abdominal wall (D). (E), Routine surgical resection specimen illustrating uterus (U), ovaries (O) and the ovarian
tumor (T). (F), Immediate postoperative (dorsal view) bioluminescent negative view indicating apparent complete surgical removal of xenografted
SKOV-3luc+ cells.
doi:10.1371/journal.pone.0089527.g003
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Discussion
Despite being the cornerstone in the treatment of ovarian
cancer, the effect of surgery has not been evaluated in preclinical
models of ovarian cancer and is currently not considered when
designing preclinical trials of new therapies. Here we have
developed a novel bioluminescent, orthotopic xenograft, surgical
model and demonstrate the application and effect of surgical
debulking in combination with chemotherapy for the very first
time.
Primary debulking surgery is the preferred initial treatment of
women with advanced ovarian cancer [29–31]. Within oncology,
the aggressive surgical approaches used in metastatic ovarian
cancer is unique, and no other malignancies have shown
demonstrable advantages of surgery in the setting of disseminated
disease [19,29]. Notably, the current preclinical EOC models have
not taken this into account. Therefore, we developed an orthotopic
and bioluminescent ovarian epithelial xenograft model to explore
the potential of surgery in preclinical therapy development. In line
with previous studies, we demonstrate that when ovarian cancer
cells are injected into the unique microenvironment of the bursal
membrane, a tumor xenograft was created [32]. Thereafter the
tumor cells disseminated into the peritoneal cavity and a disease
similar to what seen in EOC patients was established. (Fig. 1B and
1E) [8,33–35]. As the use of primary patient material in xenografts
has resulted in phenotypic heterogeneity and tumour cell
instability we decided to use a well-defined cell line and not
primary patient material [28]. The histological and immunohis-
tochemical comparison of the xenograft and the human sample
were close to identical with the exception of reduced human
vimentin staining, reflecting mouse stroma, as previously demon-
strated also in primary breast cancer xenografts [36,37]. It is
tempting to suggest the SKOV-3 xenograft as representative of a
high-grade serous EOC (Fig. 2). However a recent study revealed
the genetic profile of the SKOV-3 cells, and other frequently used
cell lines, to be different from high-grade serous ovarian tumor
samples. This implies that this orthotopic model has its limitations
and must be evaluated in this specific context before used in
preclinical studies [38]. BLI made it possible to visualise disease
progression including metastatic dissemination and development
of distal metastasis in liver and lungs (Fig. 1B and 4A), and the
intensity of the bioluminescence signal correlated with the tumour
load [27,39–41]. We subsequently developed a surgical procedure
(Fig. 3) permitting maximum cytoreduction, confirmed by BLI
(Fig. 3F). In order to standardise the methodology and surgical
procedure used, at the time of surgery all mice were operated at a
lower stage of disease than most human patients at their time of
clinical presentation [42]. Analogous to what has been observed
clinically, surgery was the treatment modality with the greatest
Figure 4. Effect of surgical treatment and chemotherapy on survival in xenografted mice. (A), Illustration of weekly bioluminescent
image analysis of representative xenografted mice in a) control treated, b) surgical treated c) chemotherapy treated (Carboplatin and Paclitaxel) and
d) surgical and chemotherapy treated mice. (B), Bioluminescence mean signal for the different treatment regimen with time. (C), Kaplan-Meyer
cumulative survival curves of control, surgery, chemotherapy, a combination of surgery and chemotherapy treated mice. (D), Mean survival week,
extended survival time (%) and number of survivors (n) in the variously treated groups.
doi:10.1371/journal.pone.0089527.g004
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impact on the outcome variables (Fig. 4C and Fig. 4D) when
compared to chemotherapy [43].
The group of mice treated with debulking surgery followed by
adjuvant chemotherapy was, similar to observations in human
studies, found to have the longest mean survival time (Fig. 4C)
[44]. After maximal cytoreductive surgery, where the primary
tumor is removed, there is no evidence of either local or distant
metastases in patients. This was illustrated also in our model, both
by the macroscopic findings after surgery and by the BLI-analysis
performed after the procedure (Fig. 3F). As all mice were
macroscopic tumor free after the cytoreductive surgery it was
interesting to note the rather large discrepancies in disease
development in the surgical cohorts with variation of 62.7 weeks.
Although we cannot rule out that sufficient cytoreduction was not
achieved and also the presence of occult metastases not visible to
the surgical team or BLI undetectable, micro-metastasis were the
most likely cause of the early relapses. To circumvent this problem
clinically, imaging (including MRI and PET/CT) has become an
important facet of presurgical planning and postoperative follow-
up. More recently, the emergence of fluorescence-based image-
guided surgery incorporating a fluorescently labeled biomarker of
an overexpressed membrane-bound protein or receptor has been
successfully translated to clinical surgery of ovarian cancer [45,46].
Preclinical development of image-guided surgery has also been
performed with human cell lines inoculated subcutaneously and
within the peritoneal cavity [46,47]. While these models are not an
accurate paradigm of human ovarian cancer, the application of
our surgical model will now permit the realistic evaluation of
image-guided surgery techniques combined with targeted drug
therapy/chemotherapeutics prior to clinical translation.
Orthotopic nude mouse models have been developed for ovary
carcinoma with surgical implantation of tissue [34,48] but with less
infiltrative and invasive growth compared to what is seen in our
model. Although inclusion of primary patient cells isolated from
ascites is a natural step in the evolution of our orthotopic model, a
recent study demonstrates the complications of phenotypic
heterogeneity and instability of human ovarian tumour cells
[28]. Therefore we suggest that application of our reproducible
cell line-based model would be more conducive in therapeutic
evaluation.
In summary, we have developed a surgical orthotopic ovarian
cancer xenograft model of SKOV-3luc+ cells resulting in a
clinically relevant metastatic disease of EOC, which could be
monitored by BLI. We demonstrate surgical intervention and
adjuvant chemotherapy for the first time in a xenograft model of
ovarian cancer, advocating this combined strategy for pre-selecting
drugs regiment with greatest promise of efficacy in human clinical
trials.
Supporting Information
Figure S1 Weight curves generated from a maximum
tolerated dose (MTD) study for the combination of
Carboplatin (C) and Paclitaxel (P) in NSG mice.
(EPS)
Acknowledgments
The authors thank Edith Fick for immunohistochemistry, Solrun Steine for
preparation of DNA fingerprints, Tereza Osdal and Siv Lise Bedringaas
for assistance in generating luciferase positive cells and Lene M. Vikebø
and Wenche Eilifsen for technical support with animal studies.
Author Contributions
Conceived and designed the experiments: BTG LB EMC. Performed the
experiments: ØH MP. Analyzed the data: ØH MP OKV AM LB EMC.
Contributed reagents/materials/analysis tools: OKV AM BTG LB EMC.
Wrote the paper: ØH MP OKV AM BTG LB EMC.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
2. Mutch DG (2002) Surgical management of ovarian cancer. Semin Oncol 29: 3–
8.
3. Zivanovic O, Aldini A, Carlson JW, Chi DS (2009) Advanced cytoreductive
surgery: American perspective. Gynecol Oncol 114: S3–9.
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, et al. (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and
paclitaxel in patients with optimally resected stage III ovarian cancer: a
Gynecologic Oncology Group study. J Clin Oncol 21: 3194–3200.
5. du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin
plus paclitaxel in advanced ovarian cancer–a new standard of care? Ann Oncol
10 Suppl 1: 35–41.
6. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance
to chemotherapy. Nat Rev Cancer 3: 502–516.
7. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for
anticancer drug activity in humans: better than commonly perceived-but they
can be improved. Cancer Biol Ther 2: S134–139.
8. Connolly DC (2009) Animal models of ovarian cancer. Cancer Treat Res 149:
353–391.
9. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of
the in vitro cell line, human xenograft, and mouse allograft preclinical cancer
models. Clin Cancer Res 9: 4227–4239.
10. Ricci F, Broggini M, Damia G (2013) Revisiting ovarian cancer preclinical
models: Implications for a better management of the disease. Cancer Treat Rev
39: 561–568.
11. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L,
et al. (2005) HSV oncolytic therapy upregulates interferon-inducible chemokines
and recruits immune effector cells in ovarian cancer. Mol Ther 12: 789–802.
12. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, et al. (2012)
Prioritizing phase I treatment options through preclinical testing on personalized
tumorgraft. J Clin Oncol 30: e45–48.
13. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation:
advantages and disadvantages. Eur J Cancer 40: 852–857.
14. Teicher BA (2006) Tumor models for efficacy determination. Mol Cancer Ther
5: 2435–2443.
15. Cordero AB, Kwon Y, Hua X, Godwin AK (2010) In vivo imaging and
therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis
Exp.
16. Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, et al. (2011)
Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-
CXCR4. Neoplasia 13: 1152–1161.
17. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR (2011) Preclinical testing of
PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian
endometrioid adenocarcinoma. Clin Cancer Res 17: 7359–7372.
18. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ, Jr., et al. (2011)
Humanized mouse model of ovarian cancer recapitulates patient solid tumor
progression, ascites formation, and metastasis. PLoS One 6: e24420.
19. Schorge JO, McCann C, Del Carmen MG (2010) Surgical debulking of ovarian
cancer: what difference does it make? Rev Obstet Gynecol 3: 111–117.
20. Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, et al. (2012) Cisplatin plus
paclitaxel and maintenance of bevacizumab on tumour progression, dissemina-
tion, and survival of ovarian carcinoma xenograft models. Br J Cancer 107: 360–
369.
21. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, et al. (2005) Ascitic
complement system in ovarian cancer. Br J Cancer 92: 895–905.
22. Lorens JB, Jang Y, Rossi AB, Payan DG, Bogenberger JM (2000) Optimization
of regulated LTR-mediated expression. Virology 272: 7–15.
23. Ke XS, Li WC, Hovland R, Qu Y, Liu RH, et al. (2011) Reprogramming of cell
junction modules during stepwise epithelial to mesenchymal transition and
accumulation of malignant features in vitro in a prostate cell model. Exp Cell
Res 317: 234–247.
24. FIGO Committee on Gynecologic Oncology (2009) Current FIGO staging for
cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic
neoplasia. Int J Gynaecol Obstet 105: 3–4.
25. Nadeau ME, Kaartinen MJ, Lague MN, Paquet M, Huneault LM, et al. (2009)
A mouse surgical model for metastatic ovarian granulosa cell tumor. Comp Med
59: 553–556.
26. Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, et al. (2013)
Factors associated with improved toxicity and tolerability of intraperitoneal
chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet
Gynecol 208: 501.e501–e507.
Surgical Mouse Model of Ovarian Cancer
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e89527
27. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, et al. (2012)
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in
acute myeloid leukemia. Leukemia 26: 910–917.
28. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, et al. (2011)
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells.
Proc Natl Acad Sci U S A 108: 6468–6473.
29. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of
ovarian carcinoma. Natl Cancer Inst Monogr 42: 101–104.
30. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary
cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413–420.
31. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, et al. (2007)
Prognostic factors for complete debulking in advanced ovarian cancer and its
impact on survival. An exploratory analysis of a prospectively randomized phase
III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian
Cancer Study Group (AGO-OVAR). Gynecol Oncol 106: 69-74.
32. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004)
Characterization of intraperitoneal, orthotopic, and metastatic xenograft models
of human ovarian cancer. Mol Ther 10: 1032–1042.
33. Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, et al. (1998) A
patient-like orthotopic implantation nude mouse model of highly metastatic
human ovarian cancer. Clin Exp Metastasis 16: 751–756.
34. Fu X, Hoffman RM (1993) Human ovarian carcinoma metastatic models
constructed in nude mice by orthotopic transplantation of histologically-intact
patient specimens. Anticancer Res 13: 283–286.
35. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53
mutations separate ovarian serous borderline tumors and low- and high-grade
carcinomas and provide support for a new model of ovarian carcinogenesis: a
mutational analysis with immunohistochemical correlation. Am J Surg Pathol
29: 218–224.
36. Czernobilsky B, Moll R, Levy R, Franke WW (1985) Co-expression of
cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii
cells of the human ovary. Eur J Cell Biol 37: 175–190.
37. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, et al. (2011) Tumor grafts
derived from women with breast cancer authentically reflect tumor pathology,
growth, metastasis and disease outcomes. Nat Med 17: 1514–1520.
38. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell
lines as tumour models by comparison of genomic profiles. Nat Commun 4:
2126.
39. Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, et al. (2013)
Sonoporation-Enhanced Chemotherapy Significantly Reduces Primary Tumour
Burden in an Orthotopic Pancreatic Cancer Xenograft. Mol Imaging Biol.
40. Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, et al.
(2013) In vivo bioluminescence imaging validation of a human biopsy-derived
orthotopic mouse model of glioblastoma multiforme. Mol Imaging 12: 161–172.
41. Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, et al. (2011) A novel
brain metastases model developed in immunodeficient rats closely mimics the
growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol 37:
189–205.
42. Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease
stage at diagnosis, and mortality. Cancer 71: 517–523.
43. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian
carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–
1259.
44. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, et al. (2000)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophos-
phamide in women with advanced epithelial ovarian cancer: three-year results.
J Natl Cancer Inst 92: 699–708.
45. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, et al. (2011)
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate
receptor-alpha targeting: first in-human results. Nat Med 17: 1315–1319.
46. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, Themelis G, et al. (2013) Real-
time near infrared fluorescence (NIRF) intra-operative imaging in ovarian
cancer using an alpha(v)beta(3-)integrin targeted agent. Gynecol Oncol 128:
590–595.
47. Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V,
Hollema H, et al. (2011) Intraoperative near-infrared fluorescence tumor
imaging with vascular endothelial growth factor and human epidermal growth
factor receptor 2 targeting antibodies. J Nucl Med 52: 1778–1785.
48. Vidal A, Munoz C, Guillen MJ, Moreto J, Puertas S, et al. (2012) Lurbinectedin
(PM01183), a new DNA minor groove binder, inhibits growth of orthotopic
primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 18:
5399–5411.
Surgical Mouse Model of Ovarian Cancer
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e89527
